Skip to Main Content

Flagship Pioneering is gearing up to launch a new company that seems to be developing precisely targeted treatments for neurodegenerative conditions, including Parkinson’s.

The new startup, dubbed Vesalius Therapeutics, will be led by Chris Austin, a high-profile recent Flagship recruit who was the founding director of the NIH’s National Center for Advancing Translational Sciences and a senior adviser to the National Human Genome Research Institute. Neurodegenerative conditions are one of his scientific areas of expertise.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment